The warning that hundreds of patients said they never received is now coming to every GLP-1 label in the United States.

According to CNN , the FDA announced that Ozempic, Wegovy, Mounjaro, Zepbound, and all other GLP-1s must carry new language about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. The rare condition can strike without pain or advance notice, cutting off blood flow to the optic nerve and leaving some patients with permanent vision loss.

The warning will appear under the labels’ “Warnings and Precautions” section, where patients and prescribers are alerted to serious potential risks.…